For the quarter ending 2026-03-31, QNCX had $12,354K increase in cash & cash equivalents over the period. -$7,627K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 35,912 | -39,458 | -13,442 | -31,079 |
| Stock based compensation | 1,286 | 1,191 | 1,255 | 2,659 |
| Depreciation and amortization | 36 | 39 | 36 | 67 |
| Change in the fair value of contingent consideration liabilities | -64,330 | 3,117 | 2,066 | 2,456 |
| Change in fair value of debt, net | -12,197 | 491 | 490 | 828 |
| Change in fair value of warrants | -31,116 | 17,297 | -291 | 4,464 |
| Non-cash goodwill impairment charge | - | 0 | 0 | 0 |
| Gain on settlement of accounts payable | 2,584 | - | - | - |
| Reclassification of cumulative translation adjustment to net income | - | 477 | - | - |
| Intangible asset impairment charge | 67,808 | - | - | - |
| Amortization of discount on available-for-sale investments | 62 | 188 | 236 | 590 |
| Change in deferred tax liabilities | - | 4,963 | - | - |
| Prepaid expenses and other current assets | 3,639 | -2,743 | 374 | -588 |
| Right of use assets, operating leases and operating lease liabilities | -28 | -24 | -27 | -53 |
| Other assets | -1,782 | -4,811 | 486 | 121 |
| Accounts payable | 5,911 | -1,154 | 1,631 | -1,417 |
| Accrued expenses and other current liabilities | -7,163 | 5,304 | -604 | 1,076 |
| Other liabilities | 701 | 742 | - | - |
| Net cash used in operating activities | -7,627 | -10,481 | -9,928 | -21,016 |
| Purchase of investments | 0 | 4,922 | 15,707 | 13,789 |
| Proceeds from maturities of investments | 12,000 | 12,997 | 14,000 | 31,000 |
| Purchase of property and equipment | 0 | 4 | 74 | 274 |
| Net cash provided by investing activities | 12,000 | 8,071 | -1,781 | 16,937 |
| Payment of contingent consideration | - | 0 | 0 | - |
| Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to private placement offering, net of issuance costs | - | 0 | 0 | 11,426 |
| Issuance of common stock in connection with the atm offerings, net of issuance costs | 14,988 | 1,997 | 1,376 | 2,890 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 | 37 | 0 | 183 |
| Repayment of borrowings | 5,545 | - | - | - |
| Net cash provided by financing activities | 9,443 | 2,034 | 1,376 | 14,499 |
| Effect of exchange rate changes on cash | -1,462 | -267 | -41 | 194 |
| Net increase in cash and cash equivalents | 12,354 | -643 | -10,374 | 10,614 |
| Cash and cash equivalents at beginning of period | 5,809 | 6,452 | 6,212 | - |
| Cash and cash equivalents at end of period | 18,163 | 5,809 | 6,452 | - |
Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. (QNCX)